Bortezomib-Thalidomide-Dexamethasone (VTD) as salvage treatment in patients with Multiple Myeloma eligible for transplantation in the real world. Long-term follow-up.

被引：0
|
作者：
Vasquez, Jule [1 ]
Quintana, Shirley [1 ]
Alcarraz, Cindy [1 ]
Villena, Marco [1 ]
Vidaurre, Tatiana [1 ]
机构：
[1] Inst Nacl Enfermedades Neoplas, Surquillo, Peru
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-223
引用
收藏
页码：S162 / S163
页数：2
相关论文
共 50 条
  • [1] Bortezomib-Thalidomide-Dexamethasone (VTD) As Salvage Treatment in Patients with Multiple Myeloma Candidates for Transplantation in the Real World
    Vasquez, Jule
    Quintana, Shirley
    Lopez, Lourdes
    Alcarraz, Cindy
    Villena, Marco
    Neciosup, Silvia
    Mas, Luis
    Gomez, Henry
    [J]. BLOOD, 2017, 130
  • [2] Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma
    Jimenez-Zepeda, Victor
    Bahlis, Nizar J.
    Duggan, Peter
    Alonso, Rafael
    Lahuerta, Juan Jose
    Valeri, Antonio
    Neri, Paola
    Tay, Jason
    Martinez-Lopez, Joaquin
    [J]. BLOOD, 2016, 128 (22)
  • [3] Bortezomib, Thalidomide and Dexamethasone Compared to Cyclophosphamide, Bortezomib and Dexamethasone As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma: Real World Experience with Multiple Myeloma Patients in Colombia
    Cesar Solano, Julio
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S248 - S248
  • [4] Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    Cavo, M.
    Pantani, L.
    Pezzi, A.
    Petrucci, M. T.
    Patriarca, F.
    Di Raimondo, F.
    Marzocchi, G.
    Galli, M.
    Montefusco, V.
    Zamagni, E.
    Gamberi, B.
    Tacchetti, P.
    Brioli, A.
    Palumbo, A.
    Sonneveld, P.
    [J]. LEUKEMIA, 2015, 29 (12) : 2429 - 2431
  • [5] Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    M Cavo
    L Pantani
    A Pezzi
    M T Petrucci
    F Patriarca
    F Di Raimondo
    G Marzocchi
    M Galli
    V Montefusco
    E Zamagni
    B Gamberi
    P Tacchetti
    A Brioli
    A Palumbo
    P Sonneveld
    [J]. Leukemia, 2015, 29 : 2429 - 2431
  • [6] Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis
    Leiba, Merav
    Kedmi, Meirav
    Duek, Adrian
    Freidman, Tzachi
    Weiss, Mia
    Leiba, Ronit
    Nagler, Arnon
    Avigdor, Abraham
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (05) : 702 - 710
  • [7] A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)
    Moreau, Philippe
    Attal, Michel
    Facon, Thierry
    Caillot, Denis
    Lenain, Pascal
    Benboubker, Lofti
    Lam, Annette
    Krotneva, Stanimira
    Proskorovsky, Irina
    Kampfenkel, Tobias
    Vanquickelberghe, Veronique
    Cote, Sarah
    Sonneveld, Pieter
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E200 - E201
  • [8] A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide-Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)
    Sonneveld, Pieter
    Dejoie, Thomas
    Zweegman, Sonja
    Merz, Maximilian
    Weisel, Katja
    Lam, Annette
    Krotneva, Stanimira
    Proskorovsky, Irina
    Kampfenkel, Tobias
    de Boer, Carla
    Cote, Sarah
    Moreau, Philippe
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E201 - E202
  • [9] Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study
    Rosinol, Laura
    Oriol, Albert
    Isabel Teruel, Ana
    Hernandez, Dolores
    Jesus Blanchard, M.
    De La Rubia, Javier
    Granell, Miquel
    Besalduch, Juan
    Palomera, Luis
    Gonzalez, Yolanda
    Asuncion Echebeste, M.
    Diaz-Mediavilla, Joaqun
    Hernandez, Miguel T.
    de Arriba, Felipe
    Carmen Gutierrez, Norma
    Luisa Martin-Ramos, M.
    Teresa Cibeira, M.
    Victoria Mateos, Maria
    Martinez-Lopez, Joaquin
    Alegre, Adrian
    Lahuerta, Juan Jose
    San Miguel, Jesus F.
    Blade, Joan
    [J]. BLOOD, 2014, 124 (21)
  • [10] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
    Mehra, Maneesha
    Cote, Sarah
    Kampfenkel, Tobias
    Nair, Sandhya
    [J]. BLOOD, 2019, 134
12345